Home » Stocks » PLXP

PLx Pharma Inc. (PLXP)

Stock Price: $12.30 USD -0.63 (-4.87%)
Updated Jun 11, 2021 4:00 PM EDT - Market closed
After-hours: $12.53 +0.23 (1.87%) Jun 11, 6:57 PM
Market Cap 280.93M
Revenue (ttm) 27,907
Net Income (ttm) -29.99M
Shares Out 16.36M
EPS (ttm) -2.57
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 11
Last Price $12.30
Previous Close $12.93
Change ($) -0.63
Change (%) -4.87%
Day's Open 12.93
Day's Range 11.97 - 12.93
Day's Volume 453,950
52-Week Range 2.72 - 16.19

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

SPARTA, N.J., June 09, 2021 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGu...

3 days ago - GlobeNewsWire

– VAZALORE 325 mg and 81 mg, the first-ever novel, liquid-filled aspirin capsules, gain FDA approval –

4 weeks ago - GlobeNewsWire

PLx Pharma (PLXP) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

1 month ago - Zacks Investment Research

SPARTA, N.J., May 03, 2021 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGua...

1 month ago - GlobeNewsWire

Increased analyst coverage over the last few weeks might lead to solid price appreciation for stocks like Guess' (GES), Babcock (BW), Wabash (WNC) and PLx Pharma (PLXP).

Other stocks mentioned: BW, GES, WNC
1 month ago - Zacks Investment Research

-- Received FDA approval of sNDAs for both VAZALORE 325 mg and 81 mg, the first-ever novel, liquid-filled aspirin capsule -- -- U.S. commercial launch of VAZALORE planned for third quarter 2021 --

3 months ago - GlobeNewsWire

SPARTA, N.J., March 11, 2021 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxG...

3 months ago - GlobeNewsWire

SPARTA, N.J., March 04, 2021 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on its clinically-validated and patent-pro...

3 months ago - GlobeNewsWire

SPARTA, N.J., March 03, 2021 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on its clinically-validated and patent-pro...

3 months ago - GlobeNewsWire

SPARTA, N.J., March 02, 2021 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on its clinically-validated and patent-pro...

3 months ago - GlobeNewsWire

PLx Pharma Inc (NASDAQ: PLXP) shares were trading higher Monday after the company announced that the U.S. Food and Drug Administration approved a supplemental new drug application for its lead products ...

3 months ago - Benzinga

-- VAZALORE is the first ever liquid-filled aspirin capsule with an innovative delivery platform indicated as a pain reliever, fever reducer and for aspirin therapy in vascular indications –

3 months ago - GlobeNewsWire

PLx Pharma Inc. (PLXP) CEO Natasha Giordano on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

--Announces $18 million private placement-- --Submitted sNDAs for VAZALORE 325 mg and 81 mg doses to FDA end of October--

6 months ago - GlobeNewsWire

-- FDA sets estimated completion review date for the end of February 2021 -- -- Targeting launch of VAZALORE for third quarter 2021 –

6 months ago - GlobeNewsWire

SPARTA, N.J., Nov. 12, 2020 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on developing its clinically-validated and ...

7 months ago - GlobeNewsWire

SPARTA, N.J., Nov. 03, 2020 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on developing its clinically-validated and ...

7 months ago - GlobeNewsWire

SPARTA, N.J., Sept. 14, 2020 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on developing its clinically-validated a...

8 months ago - GlobeNewsWire

OConnor Rita M filed a Form 4 with the SEC on Wednesday, September 2. The insider bought 4,500 shares of PLx Pharma Inc (NASDAQ:PLXP) at $3.74 on Tuesday, Sep 01, and bought 2,120 shares at $3.83 on Wed...

9 months ago - Benzinga

PLx Pharma Inc. (PLXP) CEO Natasha Giordano on Q2 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

--Bioequivalence study of VAZALORE 325 mg on track with top-line data demonstrating bioequivalence to immediate release aspirin-- --Shifting the date of sNDA filings for VAZALORE 325 mg and 81 mg doses...

9 months ago - GlobeNewsWire

SPARTA, N.J., Aug. 05, 2020 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on developing its clinically-validated an...

10 months ago - GlobeNewsWire

SPARTA, N.J., May 18, 2020 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company initially focused on developing its clinically val...

1 year ago - GlobeNewsWire

PLx Pharma Inc. (PLXP) CEO Natasha Giordano on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

-- Company to begin bioequivalence study of VAZALORE 325 mg dose ---- sNDA submissions expected by year-end -- SPARTA, N.J., May 15, 2020 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or t...

1 year ago - GlobeNewsWire

PLx Pharma Inc. (PLXP) CEO Natasha Giordano on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

-- PLx Aligning with the FDA on Data Requirements for VAZALORE  -- FDA Approves Labeling for 325 mg --  -- Expect to Launch VAZALORE in late 2020 -- SPARTA, N.J., Jan. 06, 2020 (GLOBE NEWSWIRE) -- ...

1 year ago - GlobeNewsWire

PLx Pharma, Inc. (PLXP) CEO Natasha Giordano on Q3 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

VAZALORE’S novel mechanism of action with an improved GI safety profile also delivers fast, reliable absorption and predictable antiplatelet effect establishing bioequivalence with regular aspirin. VAZA...

1 year ago - GlobeNewsWire

SPARTA, N.J., Aug. 28, 2019 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company initially focused on developing its clinically va...

1 year ago - GlobeNewsWire

PLx Pharma, Inc. (PLXP) CEO Natasha Giordano on Q2 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

PLx Pharma (PLXP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

PLx Pharma's (PLXP) CEO Natasha Giordano on Q1 2019 Results - Earnings Call Transcript

2 years ago - Seeking Alpha

PLx Pharma (PLXP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 years ago - Zacks Investment Research

About PLXP

PLx Pharma Inc., a specialty pharmaceutical company, focuses on developing the PLxGuard drug delivery system to provide various products in the United States. The company's lead product candidates are Vazalore 325 mg and Vazalore 81 mg, which are formulations of aspirin that use the PLxGuard delivery system, which provides patients with vascular disease and diabetic patients who are candidates for aspirin therapy based on physician recommendation, with fast, reliable, and predictable platelet inhibition as compared to enteric-coated aspirin, as... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
Founded
2002
Stock Exchange
NASDAQ
Ticker Symbol
PLXP
Full Company Profile

Financial Performance

In 2020, PLx Pharma's revenue was $30,430, a decrease of -94.62% compared to the previous year's $565,464. Losses were -$15.21 million, -25.81% less than in 2019.

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for PLx Pharma stock is "Buy." The 12-month stock price forecast is 16.00, which is an increase of 30.08% from the latest price.

Price Target
$16.00
(30.08% upside)
Analyst Consensus: Buy